Analysis of Antiemetic Premedication Administration Timing on Nausea and Vomiting Incidence among Breast Cancer Patients Receiving Chemotherapy

The risk factors affecting chemotherapy-induced nausea and vomiting (CINV) includes antiemetic premedication time pattern, and this study investigates the capability of enhancing this in breast cancer patients receiving high emetogenic chemotherapy (HEC). Furthermore, this observational research was implemented at the oncology unit of Dr. Soetomo General Hospital Surabaya over a three-month period involving 69 female patients. The results showed unspecific antiemetic premedication timing in comparison to those with recommended timeframes, was connected with greater occurrence of both acute nausea in all cycles of chemotherapy (p<0.05), and acute vomiting in second and third cycles (p<0.05) but not in the first cycle (p=0.49). However, specific time administration of antiemetic treatment was linked with lower incidence of delayed nausea in all cycles (p<0.05), and less delayed vomiting in second and third cycles (p<0.05) but not in first cycle (p=0.10). These findings indicate specific time administration of antiemetic drugs causes significant advantages in mitigating CINV among breast cancer patients treated with emetogenic chemotherapy, and significantly lessened the occurrence of acute and delayed nausea and vomiting.